Accessibility help Skip to navigation Skip to content Skip to footer

AstraZeneca

AstraZeneca’s vaccine has saved many thousands of lives. But rare side-effects, and, relative to competitors, lower efficacy against new variants have given it an uncertain outlook. Coupled with a multibillion-euro lawsuit over delivery shortfalls, the UK pharma group’s future role in the ongoing battle against Covid-19 is under scrutiny

© FT montage

Does the AstraZeneca vaccine have a future?
Hit by a multibillion-euro lawsuit and rare side-effects, the jab that was going to save the world has an uncertain outlook
AstraZeneca chief says ‘vaccine has a future’ after setbacks
Pascal Soriot reveals the UK had priority access to the jab and says there is new evidence it works against variants
Pascal Soriot: the pharma CEO navigating a vaccine storm
The AstraZeneca chief is caught in the crossfire over a Covid-19 jab that could save millions
Disputes leave AstraZeneca boss with chronic vaccine headache
Questions mount over whether Soriot’s dash and drive, which enthral investors, have resulted in missteps
How AstraZeneca’s vaccine was hit by flawed trials, defects and politics — but might still save the world
Vaccine maker under pressure over clinical trial data and manufacturing problems